首页> 外国专利> METHOD FOR MATURING CARDIOMYOCYTE, METHOD FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, METHOD FOR PURIFYING MATURE CARDIOMYOCYTE, METHOD FOR ASSISTING DRUG DEVELOPMENT, METHOD FOR TREATING HEART DISEASE, MATURE CARDIOMYOCYTE MARKER, REPORTER CELL, MATURE CARDIOMYOCYTE, DEVICE FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, PROGRAM FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, KIT FOR MATURING CARDIOMYOCYTE, AND KIT FOR PURIFYING CARDIOMYOCYTE

METHOD FOR MATURING CARDIOMYOCYTE, METHOD FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, METHOD FOR PURIFYING MATURE CARDIOMYOCYTE, METHOD FOR ASSISTING DRUG DEVELOPMENT, METHOD FOR TREATING HEART DISEASE, MATURE CARDIOMYOCYTE MARKER, REPORTER CELL, MATURE CARDIOMYOCYTE, DEVICE FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, PROGRAM FOR EVALUATING MATURATION DEGREE OF CARDIOMYOCYTE, KIT FOR MATURING CARDIOMYOCYTE, AND KIT FOR PURIFYING CARDIOMYOCYTE

机译:生成心肌细胞的方法,用于评估心肌细胞成熟程度的方法,纯化成熟心肌细胞的方法,辅助药物发育的方法,治疗心脏病,成熟心肌细胞标志,报告细胞,成熟心肌细胞,评估心肌细胞成熟程度的方法用于评估心肌细胞的成熟程度,用于成熟的心肌细胞,以及用于纯化心肌细胞的试剂盒

摘要

Provided is a method for maturing a cardiomyocyte, whereby it becomes possible to obtain a maturated mature cardiomyocyte. One component selected from the group consisting of a specific nuclear receptor agonist, a maturation-promoting compound and a transcriptional factor capable of promoting the maturation of a cardiomyocyte or an arbitrary combination of these components is added to an immature cardiomyocyte. As a result, the immature cardiomyocyte can be matured to give a mature cardiomyocyte. Among the above-mentioned components, a nuclear receptor agonist is one component selected from the group consisting of a hormone, an RXR agonist, a PPAR agonist and an ROR agonist or an arbitrary combination of these components, and the maturation-promoting compound is an HIF1a inhibitor.
机译:提供了一种用于成熟心肌细胞的方法,由此可以获得良好的成熟心肌细胞。将一种组分选自特定的核受体激动剂,促进促进化合物和能够促进这些组分的任意组合的成熟化合物和能够促进这些组分的任意组合的转录因子。结果,可以成熟未成熟的心肌细胞以产生成熟的心肌细胞。在上述组分中,核受体激动剂是选自激素,RXR激动剂,PPAR激动剂和ROR激动剂或这些组分的任意组合的一种组分,并且成熟的化合物是一种HIF1A抑制剂。

著录项

  • 公开/公告号WO2021112115A1

    专利类型

  • 公开/公告日2021-06-10

    原文格式PDF

  • 申请/专利权人 JICHI MEDICAL UNIVERSITY;

    申请/专利号WO2020JP44816

  • 发明设计人 UOSAKI HIDEKI;

    申请日2020-12-02

  • 分类号C12N5/10;A61K35/34;A61L27/36;A61L27/38;A61L27/40;A61P9;A61P21;A61P43;C12M1/34;C12N5/077;C12N15/63;C12Q1/24;C12Q1/6897;G01N33/53;

  • 国家 JP

  • 入库时间 2022-08-24 19:17:32

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号